|Brand name (active ingredient)||Disease Area||Approved and marketed||Owner|
|Chenodeoxycholic acid Leadiant (chenodeoxycholic acid)||Cerebrotendinous Xanthomatosis||Approved in the EU||Leadiant Biosciences Ltd.|
|Natulan (procarbazine)||*Hodgkin lymphoma and brain cancers||*Approved in the EU||Leadiant Biosciences Ltd.|
Updated June 2017
*List not exhaustive.
For patients: if you wish to report an adverse event related to one of our products, please contact your healthcare provider. In addition, you can contact us on firstname.lastname@example.org.
For healthcare professionals: if you wish to report an adverse event related to one of our products, please follow the current regulatory procedure in force in your country or contact us at email@example.com.
If your residence is in the U.S. or Canada, please consult the North American website for details on safety reporting.